Prices delayed by at least 15 minutes | Print


Oncimmune Holdings PLC (ONC)

ORD 1P
Sell: 20.6p|Buy: 21.8p|Change: 0.20 (0.95%)

Open 

21p


Previous close 

21p


Trade high 

21.35p


Volume 

12,949


Year high 

45.00p


Year low 

13.00p


Dividend yield 

-


Market capitalisation 

£15.72 mn


P/E ratio 

-


ISIN 

GB00BYQ94H38


This share can be held in a Dealing accountISALifetime ISAJISASIPPand can be used with Dividend reinvestment

Share price

Performance 27/03/2024

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann


Total return (%)
Oncimmune Holdings PLC+ 2.94
FTSE AIM All Share+ 0.35
More...

Company profile

Oncimmune Holdings PLC is engaged in diagnosing cancer. It is involved in the development, manufacture, and commercialization of personalized immunodiagnostics for the screening, detection, and care of cancer. The company's operating segment is ImmunoINSIGHTS.

Sector 

Healthcare


News

Recent trades

DateTimePriceQuantityValue (£)
28/03/202412:34:5520.7441,000207.44
28/03/202411:03:1221.3510,0002,135.00
28/03/202408:00:12211,949409.29
27/03/202403:03:0720.456714146.06
27/03/202410:52:1021.4730,2576,496.18

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2024 AJ Bell. All rights reserved.